AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03177083
Drug: interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Per SMPC
Trial: NCT01612260
Drug: Shensong Yangxin capsule
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
Trial: NCT04505228
Drug: Safflower (Carthamus Tinctorius) IgG4 &#X7C; Serum &#X7C; Allergy
DrugBank: Safflower (DB10905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The designed Chinese herb formulas
Trial: NCT04505228
Drug: Atropine Sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The basic treatment for heart disease
Trial: NCT01472497
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pioglitazone (15mg) once a day for 24 weeks
Trial: NCT00778037
Drug: Cyclobenzaprine hydrochloride 10 mg tablet
RxNorm normalized name: cyclobenzaprine
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00540878
Drug: SB-751689 oral tablets (400 mg)
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02127190
Drug: CXA-10 emulsion
RxNorm normalized name: CXA-10
DrugBank: CXA-10 (DB15026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
Trial: NCT04338958
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment
Trial: NCT03361397
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion
Trial: NCT03361397
Drug: Distilled Water
RxNorm normalized name: Distilled Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled Water will be used via mask nebulizer before LMA insertion
Trial: NCT03302845
Drug: Omeprazole 40 MG
RxNorm normalized name: omeprazole 40 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg capsule
Trial: NCT03302845
Drug: Famotidine 40 mg
RxNorm normalized name: famotidine 40 MG
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg tablet
Trial: NCT03302845
Drug: Telotristat ethyl 250 mg
RxNorm normalized name: telotristat ethyl 250 MG
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat ethyl 250 mg tablet
Trial: NCT00810030
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
Trial: NCT00810030
Drug: Iron Sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is \>25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height \[m\] x height \[m\].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit.
Trial: NCT03350217
Drug: Hetastarch
RxNorm normalized name: Hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
Trial: NCT01375244
Drug: Lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 10 mg, single dose
Trial: NCT01375244
Drug: Zestril
RxNorm normalized name: Zestril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, 10 mg, single dose
Trial: NCT00285805
Drug: Rosiglitazone versus placebo
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00285805
Drug: response (sodium excretion) to furosemide infusion
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04456959
Drug: Inotuzumab Ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.
Trial: NCT01496612
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01420744
Drug: BT086
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period.
Trial: NCT00291577
Drug: Sunitinib (Sutent)
RxNorm normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
Trial: NCT00291577
Drug: Taxotere
RxNorm normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taxotere 75 mg/m2 iv, once every 3 weeks
Trial: NCT00390468
Drug: Tandutinib
RxNorm normalized name: Tandutinib
DrugBank: Tandutinib (DB05465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
Trial: NCT00830362
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg administered once
Trial: NCT01087645
Drug: NN9925 (i.v.)
RxNorm normalized name: esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
Trial: NCT02706730
Drug: OTO-104
RxNorm normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of 12 mg OTO-104
Trial: NCT00611247
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide
Trial: NCT03181113
Drug: Peginterferon Alfa-2B
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pre-received standard peginterferon alfa-2b therapy
Trial: NCT03181113
Drug: Peginterferon Alfa-2A
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pre-received standard peginterferon alfa-2a therapy
Trial: NCT03021642
Drug: Tepotinib test (Treatment Period 1)
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 1 (Day 1)
Trial: NCT03021642
Drug: Tepotinib reference (Treatment Period 2)
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 2 (Day 22)
Trial: NCT03021642
Drug: Tepotinib reference (Treatment Period 1)
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 \* 100 mg tablet) in Treatment period 1 (Day 1)
Trial: NCT03021642
Drug: Tepotinib test (Treatment Period 2)
RxNorm normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 \* 500 mg tablet) in Treatment period 2 (Day 22)
Trial: NCT01028586
Drug: Safinamide, MAO-B inhibitor
DrugBank: Safinamide (DB06654)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
Trial: NCT01028586
Drug: Safinamide, MAO-B inhibitor
DrugBank: Safinamide (DB06654)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
Trial: NCT00545662
Drug: citicoline
RxNorm normalized name: Citicoline
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
Trial: NCT01811251
Drug: Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04197492
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib once daily (12mg/d) on days 1-14 of a 21-day cycle.
Trial: NCT02626611
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
Trial: NCT01415986
Drug: Temoporfin
RxNorm normalized name: Temoporfin
DrugBank: Temoporfin (DB11630)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
Trial: NCT02626611
Drug: Food Flour Buildup
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
Trial: NCT00828659
Drug: Lorcaserin Dose #1
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00828659
Drug: Lorcaserin Dose #2
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00828659
Drug: Lorcaserin Dose #3
DrugBank: Lorcaserin (DB04871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02756013
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
Trial: NCT02756013
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
Trial: NCT03099486
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
Trial: NCT03099486
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
Trial: NCT01754649
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
Trial: NCT00195741
Drug: divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02745561
Drug: Endostatins
RxNorm normalized name: Endostatins
DrugBank: Endostatin (DB06423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
Trial: NCT02745561
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
Trial: NCT02052557
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
Trial: NCT02052557
Drug: Bupivacaine liposome suspension
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
Trial: NCT00374244
Drug: Pimozide
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: half of the subjects are randomized to the active drug group
Trial: NCT00889044
Drug: clopidogrel by chewing
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg clopidogrel by chewing
Trial: NCT03280979
Drug: high dose methotrxate
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
Trial: NCT00584870
Drug: PF-04383119 (RN624)
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of 200 micrograms/kg RN624 on Day 1
Trial: NCT00411554
Drug: sitagliptin phosphate
RxNorm normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
Trial: NCT00411554
Drug: Comparator: voglibose
DrugBank: Voglibose (DB04878)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
Trial: NCT03216356
Drug: D-Cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg DCS (derived from Seromycin 250 mg capsules)
Trial: NCT01331434
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet
Trial: NCT01891331
Drug: VT-1161
RxNorm normalized name: VT-1161
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01891331
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00727493
Drug: alendronate once weekly 70mg
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
Trial: NCT03507491
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).
Trial: NCT03507491
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
Trial: NCT01169558
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
Trial: NCT00302744
Drug: Psilocybin (drug)
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule (.2 mg/kg).
Trial: NCT03369964
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle
Trial: NCT03369964
Drug: Emactuzumab
RxNorm normalized name: Emactuzumab
DrugBank: Emactuzumab (DB14905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle
Trial: NCT03369964
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle
Trial: NCT02018627
Drug: Xeris glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subject is given an injection of xeris glucagon
Trial: NCT02018627
Drug: Lilly glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subject is given an injection of lilly glucagon
Trial: NCT00299832
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00592111
Drug: intensive chemo with concurrent growth factor
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
Trial: NCT02097004
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continue Entecavir(0.5mg) for 100 weeks
Trial: NCT00160628
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04158739
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT